Founding Honorary Board
Dr. Marc Potenza is a board-certified Psychiatrist with sub-specialty training and certification in addiction psychiatry. He has trained at Yale University receiving a combined BS/MS with Honors in Molecular Biochemistry and Biophysics and a PhD in Cell Biology, the latter concurrent with the MD through the Medical Scientist Training Program. He completed internship, psychiatric residency and addiction psychiatry fellowship training at Yale. Currently, he is a Professor of Psychiatry, Child Study and Neurobiology at the Yale University School of Medicine where he is Director of the Problem Gambling Clinic, the Center of Excellence in Gambling Research, and the Women and Addictive Disorders Core of Women's Health Research at Yale. He is on the editorial boards of ten journals (including editor-in-chief of Current Addiction Reports) and has received multiple national and international awards for excellence in research and clinical care. He has consulted to the Substance Abuse and Mental Health Services Administration, National Registry of Effective Programs, National Institutes of Health, American Psychiatric Association and World Health Organization on matters of addiction. He has participated in two DSM-5 research work groups, addressing topics relating to gambling, impulse control, and addiction.
Dr. Potenza's research has focused on the neurobiology and treatment of substance and non-substance addictions and other disorders characterized by impaired impulse control and reward-related motivations. The majority of this work has focused on understanding clinical and neurobiological underpinnings of these disorders, and their co-occurrences with other mental health disorders, in order to advance prevention and treatment strategies. Dr. Potenza's research has applied brain imaging, genetic, epidemiological and clinical trials methodologies to gain knowledge and improve prevention and treatment strategies for addictive disorders. This work has also involved identifying potential intermediary phenotypes, like facets of impulsivity, that may in part explain the high rates of co-occurrence between psychiatric conditions and might represent novel targets for prevention and treatment strategies.
Marc Potenza, MD, PhD
Yale University, USA
Non-Substance or Behavioral Addictions
Eric J. Nestler, MD, PhD
Mount Sinai School of Medicine, USA
Molecular Mechanism of Addiction
Dr. Mark S. Gold is a translational researcher, author, and inventor best known for his pioneering work on the brain systems underlying the effects of opiate drugs, cocaine, and overeating. His research career started in 1972 and he has been a prolific author of more than 1,000 academic texts, abstracts, articles and chapters. Starting in the lab and teaching Neuroscience, his research in the 1970s in this area led to a dramatic change in the way opiate action was understood. He proposed a novel model for opiate action, dependence, and withdrawal. This locus coeruleus theory of opiate and drug withdrawal is a mainstay of 2014 theory and practice, even though he proposed it in 1978.
Dr. Gold was awarded the 2006 Nelson J Bradley award by NAATP, the American Psychiatric Associations Foundations Fund Award & Prize, China Academy of Sciences and other prestigious awards. Most recently (2015), he was awarded the John P McGovern award and prize by ASAM at the ASAM Annual Convention for his distinguished career.
Mark S. Gold, MD
University of Florida, USA
Andrew Smolen, PhD
University of Colorado at Boulder, USA
Dr. Michael Ritsner, MD, PhD is an Associate Professor of Psychiatry at the Rappaport Faculty of Medicine, Israel Institute of Technology (Technion) in Haifa, Israel. He also serves as Head of the Acute Department of the Sha'arMenashe Mental Health Center. Dr. Ritsner is certified by the Israeli Board of Psychiatry. He has over 40 years of experience in psychiatry, medical genetics, education, and research, and has held administrative and teaching positions at numerous institutions. Dr. Ritsner is internationally renowned for his research in schizophrenia spectrum disorders. Particular areas of interest include anhedonia, neurosteroids, neuroprotection, and quality of life deficit syndrome.Dr. Ritsner has published over 180 articles,reviews, and book chapters and has lectured widely in national and international scientific forums. He has given more than 200 presentations including as invited speaker at scientific conferences and medical education events. His research work has been supported by grants from the Stanley Foundation (USA). Dr. Ritsner is the co-author of two books on neuropsychiatry and editor of series follows 14 volumes, which provide a comprehensive up-to-date state of the art overview of the literature that addresses the challenges facing clinical and biological psychiatry.
Michael Ritsner, MD
Sha'ar Menashe Mental Health Center, Israel
Schizophrenia Spectrum Disorders
Dr. David E. Smith is recognized as a national leader in the treatment of addictive disease, the psychopharmacology of drugs, new research strategies in the management of drug abuse problems, and appropriate prescribing practices for physicians. He teaches that addiction is a primary medical illness which is best treated in a multidisciplinary fashion, utilizing the group process and the 12-Step programs of Alcoholics Anonymous, Narcotics Anonymous and Cocaine Anonymous.
Dr. Smith lectures on the management of psychoactive drug dependence, including cocaine, alcohol and prescription drugs. He also speaks on the subjects of impaired and recovering clinicians, substance abuse in the workplace, dual diagnosis disorders, and substance abuse and the criminal justice system, among many other topics. He provides medical review of DOT and private industry drug testing and prescription drug plans, and legal consultation.
Dr. Smith founded the Haight Ashbury Free Clinics in 1967, inaugurating the principle of “Health Care is a Right, not a Privilege.” He has served on federal, state and local bodies addressing substance use, abuse and treatment, and has received numerous awards, including the 2013 Peter E. Haas Award from the University of California Berkeley. He lectures extensively and is the author/co-author of over 360 professional articles and books, including Unchain Your Brain: 10 Steps to Breaking the Addictions that Steal Your Life, with Dr. Daniel Amen.
David E. Smith, MD
University of California at San Francisco, USA
Mauro Ceccanti, MD
University of Rome, Italy
Molecular Basis of Alcoholism
Dr. Marlene Oscar-Berman is professor of psychiatry, neurology, and anatomy & neurobiology, as well as a research career scientist at the Veterans Affairs (VA) Boston Healthcare System. To date, she has published approximately 200 peer-reviewed manuscripts, invited reviews, and book chapters. She has made major contributions in multiple distinct areas, but is probably best known for her insightful work on brain mechanisms associated with perceptual, emotional, and cognitive impairments in chronic alcoholics with and without Korsakoff’s syndrome. Dr. Berman’s contributions to science have been recognized with numerous awards and honors, ranging from a Fulbright scholarship, to awards for excellence in research from the Massachusetts Neuropsychological Society, the Research Society on Alcoholism, and the Distinguished Career award from the International Neuropsychological Society, to name a few.
Marlene Oscar-Berman, PhD
Boston University, USA
Mark Griffiths, PhD
Nottingham Trent University, UK
Philip Gorwood, MD, PhD
Paris Descartes University, France
Frederick Toates, DPhil, DSc
The Open University, UK
Motivation Incentive Sex Drugs
Dr. Horace Loh, a graduate of National Taiwan University, earned his Ph.D. in biochemistry in 1965 from the University of Iowa and completed a postdoctoral fellowship in the Department of Pharmacology at the University of California, San Francisco in 1967. He later joined their faculty in the Departments of Psychiatry and Pharmacology. Twenty years into a successful career at the UCSF Medical Center, Dr. Loh accepted the headship of the Department of Pharmacology at the University of Minnesota in 1989. The year following his appointment as Head of Pharmacology, he was named Frederick and Alice Stark Professor in Neuroscience by the Medical School. In 2010, he was named a Regents Professor at the University of Minnesota- the highest honor the University can bestow to its faculty members. Dr. Loh has published over 500 original research papers and has trained approximately 30 Ph.D. students and 100 postdoctoral fellows. He has received several major awards in his field, including, most recently, the Founder’s Lecture Award from the International Narcotics Research Conference (2007); the University of Iowa Carver College of Medicine’s Distinguished Alumni Award for Achievement (2007); the Nathan B. Eddy Award for Lifetime Achievement in Drug Dependence Research from the College on Problems of Drug Dependence (2002); the Otto Krayer Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET) (1999), and the Pharmaceutical Research and Manufacturers of American (PhRMA) Foundation Award in Excellence for Basic Pharmacology (1999).
Horace Loh, PhD
University of Minnesota, USA
Opiates and Opioids
David E. Comings, MD
City of Hope National Medical Center, USA
Dr. Tomas Palomo, MD by the Complutense University of Madrid in 1971, PhD in neuroanatomy by the University of Valladolid in 1974. In 1971 his university activity begins as assistant professor of Neuroanatomy at Valladolid Medical School and since then has led multidisciplinary clinical-preclinical investigation groups studying the cerebral basis of psychiatric disorders in Spain and the United Kingdom.
From 1976 to 1978 in MRC Brain Metabolism Unit at Edinburgh he works on the molecular basis of Schizophrenia using animal models of dopamine supersensitivity. From 1980 to 1984 in Aberdeen University he develops animal models for the study of schizophrenia, depression and addictive disorders.
From 1979 he is Lecturer of Psychiatry in the Universities of Newcastle (1979-1980), Aberdeen (1980-1984) and from 1985 to the present, professor of Psychiatry in the Complutense University of Madrid, Spain. From 1990 head of Psychiatry Department of “University Hospital 12 of October” of Madrid, he organized a Mental Health Services Network to attend Area 11 of Madrid with 900,000 inhabitants and created a base of clinical and biological investigation. At “University Hospital 12 of October” he set up the Unit for the investigation and treatment of addictive disorders (1995), organizes a research group for the study of schizophrenia with neuroimaging techniques (1996), a Unit for basic experimental neuropsychopharmacology (1998) and the Unit for genetic studies (2002). His main research interest is the dopaminergic system and its involvement in schizopsychotic and addictive disorders, and, in relation to these, of personality disorders and impulsivity. At present he is the national coordinator of the schizophrenia programme of CIBERSAM (National Spanish Research Net for Biomedical Research in Mental Disorders) and member of its executive committee. He was the Director of the Official School of Psychiatry from 1989 to 2004, and President of the Natonal Commission of Psychiatry in Spain from 1995 to 2006.
Since he started research, clinical and teaching activities in 1971 he has been very active in promoting multidisciplinary clinical-basic research in Spain. In 1993 he founded the Fundacion Cerebro y Mente, multidisciplinary non-profit organization dedicated to the promotion and development of basic and applied neurosciences. He has organized 29 national and international scientific congresses in Spain on neuroscientific advances and their relevance to psychiatry, and has published over 200 scientific publications. He is editor of the national series of books “Avances Neurocientíficos y Realidad Clinical” (10 volumes) and the international series: “Strategies for Studying Brain Disorders” (11 volumes).
At present he is in Madrid as Professor of Psychiatry in the Complutense University of Madrid; Coordinator of Neurosciences Research and President of the Scientific Committee at “University Hospital 12 of October” and “Institute i+12”; Head of Group 19 of CIBERSAM; and he is also President of the Foundation Cerebro y Mente.
Tomas Palomo, MD, PhD
Universidad Complutense de Madrid, Spain
Associate Editorial Board
Panayotis K. Thanos, PhD
Research Institute on Addictions at University at Buffalo,USA
Jhodie Duncan, PhD
University of Melbourne, Australia
Zsolt Demetrovics, PhD
Eötvös Loránd University, Hungary
Substance Use Disorder
Internet Gaming Disorder
Igor Elman, MD
Harvard Medical School, USA
Thomas Simpatico, MD
University of Vermont, USA
Medicine and the Law/Public Policy
Decision Support System Design
M. Foster Olive, PhD
Arizona State University, USA
A. Kenison Roy, MD
Tulane University Medical School, USA
Dr. Edward Modestino is a multimodal neuroimaging expert. He has used neuroimaging (fMRI, fcMRI, DTI, SPECT) and electrophysiology (EEG, SC, and plethysmography) as tools to study cognition, attention, perception, and altered states of consciousness, with a particular interest in psychopathologies (ADHD, narcolepsy, and Parkinson's disease). He plans to study the connection between ADHD and Narcolepsy within the framework of RDS using a connectomic approach, combining neuroimaging and genetic screening. He is a Research Assistant Professor of Neurology at Boston University School of Medicine.
Edward Modestino, PhD
Massachusetts College of Pharmacy and Health Sciences, USA
Bryan K. Yamamoto, PhD
Indiana University School of Medicine, USA
Brett Haberstick, PhD
University of Colorado at Boulder, USA
Dr. Subhash C. Pandey received his PhD from the Pharmacology division of the Central Drug Research Institute in Lucknow, India and then received his postdoctoral training in neuropsychopharmacology in the Department of Psychiatry, University of Illinois at Chicago. He is currently Professor of Psychiatry, Anatomy and Cell Biology and director of neuroscience alcoholism research at University of Illinois at Chicago, Chicago. Dr Pandey also holds position as a VA Career Scientist at the Jesse Brown VA Medical Center, Chicago. He is well known for his scientific contributions towards molecular and cellular neuroscience of alcoholism and anxiety disorders. He is an active member of the Research Society on Alcoholism (RSA), International Society for Biomedical Research on Alcoholism (ISBRA) and several other scientific societies, and a fellow of the Indian Academy of Neurosciences and Collegium Internationale Neuro-sychophamacologicum (CINP). His research has given valuable scientific knowledge for the better understanding of pathophysiology of complex brain diseases, such as addictive behaviors. Several of his scientific discoveries have been highlighted by the National Institutes of Health. Dr. Pandey has received various honors and awards, most notably the 2010 Bowles Lectureship Award in alcoholism research by University of North Carolina at Chapel Hill, USA and Mario Toppo Distinguished Scientist Award by Association of Scientists of Indian Origin in America in 2014.
Subhash Pandey, PhD
University of Illinois at Chicago, USA
Neurobiology of Alcoholism
Marcelo Febo, PhD
University of Florida, USA
Effects of Maternal Drug Exposure
Drug use Disorders in Animal Models
Dr. Yijun Liu received his PhD in Physiology at the University of Texas Health Science Center in San Antonio, Texas. He is currently the River Branch Professor at the University of Florida College of Medicine and has been a tenured Professor there as well. His area of expertise is in magnetic resonance imaging methodology and image processing, innovations, and applications in neuroscience such as addiction, obesity, autism and depression. He has received numerous awards such as the Independent Researcher Award by National Alliance for Research in Schizophrenia and Depression (NARSAD), 2010; College of Medicine Senior Faculty Award by UF International Center, 2009; The Oversea Outstanding Young Investigator Award (B Category) by NSFC, 2006 (China); Young Investigator Award by National Alliance for Research in Schizophrenia and Depression (NARSAD), 2001; Bristol-Myers Squibb Award by American College of Neuropsychopharmacology (ACNP), 2000; Student Stipend Awards, International Society of Magnetic Resonance in Medicine, 1997 and 1998; and Best Presentation Award, Society For Neuroscience, Texas Chapter, 1995. He has been an Editorial Board Member for the American Journal of Traditional Chinese Veterinary Medicine. Liu has served as a reviewer in various peer-reviewed journals and on several grant/NIH sections.
Yijun Liu, PhD
University of Florida, USA
Debmalya Barh, PhD
Institute of Integrative Omics and Applied Biotechnology, India
Intergrative Omics-based Biomarkers
Kelvin Lim, MD
University of Minnesota, USA
David Baron is currently Professor and Vice Chair, and Chief of Psychiatry at University Hospital at the Keck School of Medicine, University of Southern California. Dr. Baron is also the Director of the Global Center for Exercise, Psychiatry and Sport at USC and Chairman of the Section on Exercise, Psychiatry and Sport for the World Psychiatric Association/World Health Organization. He is also a current member of the Executive Board of Directors for the International Society of Sports Psychiatrists and the 2010 Consumer Council of America "Top Doc" for Sport Psychiatry.
Dr. Baron is the former Deputy Clinical Director of the National Institute of Mental Health and Chair of the Department Psychiatry at the NIH graduate school 1989-1997 and Temple University (1998-2010).
He developed, and holds the copyright on the only validated depression screener specifical for athletes (BDSA), which is currently in use in over 7 countries. He has over 30 years of clinical experience in sports medicine and sports psychiatry and has worked with athletes of all ages and levels of competition including NCAA, Olympic, and professional. He has published over 130 peer reviewed publications and presented over 300 scientific presentations in the US and over 30 invited international talks, many in the area of Doping in Sports and Depression, Drug Use and Concussion in athletes. His current clinical and research interests are in the neuropsychiatric sequel of recurrent sub-clinical concussion and TBI in athletes, specifically focused on developing more sensitive, user-friendly screening instruments and methods, and increasing public awareness of this growing problem.
David Baron, DO, MSEd
Keck School of Medicine of USC, USA
Global MH Public Literacy
Neuropsych aspects of Repetitive mTBI
Marco Diana, MD, PhD
University of Sassari, Italy
Neuroscience of Addiction
At 7 years, Dr. Trevor Archer was sent to St. Joseph’s College (school), North Point, Darjeeling, and from 15-17 years he attended Wallington Grammar School, Wallington, Surrey, UK. During this time he was part-time stable lad, Epsom, Surrey. With ‘O’-levels, he was offered a position at the Institute of Animal Physiology, Babraham, UK, and took his HND qualification at Cambridge Polytechnical College, Cambridge, UK (1971). Thereafter, he obtained an Honour’s degree (Psychology and Physiology) at Newcastle-upon-Tyne University (1974), and a PhD, Uppsala University, Uppsala, Sweden (1979). From 1978 (Aug) to 1988 (Dec), he was employed by Astra Läkemedel AB with the position of Head of CNS Drugs when he left to take up his appointment as Professor and Chair of Biological Psychology. Dr. Archer have the position of Guest or Visiting Professor at: University of Hawaii at Manoa, Örebro University, Karlstad University, Kalmar University, Madrid University and received an Outstanding Lifetime Achievement Award from St. Joseph’s College, North Point (2010); Honorary Doctorship,: Professorship and Membership Awards from the Polish Academy of Science Pharmacological Society (may, 2013); and the Sansone Award (April, 2014): School of Medicine, Washington University, St. Louis, Missouri.
Trevor Archer, PhD
University of Gothenburg, Sweden
Dr. Jag Khalsa, with about 50 years of experience in drug research, serves as the Chief of the Medical Consequences Branch, National Institute on Drug Abuse, NIH, DHHS; is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others). Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He also serves on numerous Federal and NIH level committees including the HHS Viral Hepatitis Implementation Group (VHIG), National Commission on Digestive Diseases and its two sub-committees (Liver Research, Diabetes Research), Federal Task Force on TB, NIH Steering Committee on Centers for AIDS Research, and Human Microbiome Workgroup. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, Society of Neuro-Immune-Pharmacology (SNIP), Life Time Achievement Awards from SNIP and International Conference on Molecular Medicine (India) and MIT, India; a commendation from the US Congress, Awards of Merit from the International Society of Addiction Medicine (ISAM), the President of the American Society of Addiction Medicine (ASAM), and a Certificate of Appreciation from the Office of Assistant Secretary for Health (Drs. Howard Koh and Ron Valdiserri), DHHS. He has a PhD in neuro-psycho-pharmacology, a Master’s degree in herbal pharmacology, post-doctoral training in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International.
Jag Khalsa, MS, PhD
National Institute on Drug Abuse, USA
Dr. Peter R. Martin, MD, MSc is Professor of Psychiatry and Pharmacology at Vanderbilt University School of Medicine and Director of the Vanderbilt Addiction Center. Dr. Martin received an Honours BSc in Molecular Genetics, in 1971 and the MD, CM, in 1975, both from McGill University and an MSc (Pharmacology) from the University of Toronto, in 1979. He was Resident in Internal Medicine (1975-1976), Fellow in Clinical Pharmacology (1976-1978), and Resident in Psychiatry (1978-1980) all at the University of Toronto. Subsequently he was a Visiting Scientist in the Section of Experimental Therapeutics, Laboratory of Clinical Science, National Institute of Mental Health (1980-1983); Chief of the Section of Clinical Science, Laboratory of Clinical Studies at the National Institute on Alcohol Abuse and Alcoholism (1983-1986); and Associate Professor in the Departments of Psychiatry & Pharmacology at Vanderbilt University (1986-1992).His research program has been funded by the National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse as well as foundation and pharmaceutical industry support.
Peter R. Martin, MD
Vanderbilt University School of Medicine, USA
Opioid use Disorder
Dr. Wayne L. Westcott, PhD, teaches exercise science and conducts strength training research at Quincy College in Quincy, Massachusetts. Dr. Westcott has been a strength training consultant for numerous organizations, including the United States Navy, the United States Air Force, the American Council on Exercise, the YMCA of the USA, and Nautilus. He has authored 25 books and textbooks, and more than 60 peer-reviewed academic papers.Dr. Westcott served as an editorial advisor, reviewer, writer, and columnist for many publications, including The Physician and Sports medicine, ACSM’s Health & Fitness Journal, ACSM’s Certified News, Fitness Management, Perspective, On-Site Fitness, Prevention, and Shape. He has been a keynote speaker for national meetings of the American College of Sports Medicine, the American College of Nutrition, the National Intramural and Recreational Sports Association, Harvard University School of Medicine, and Creighton University School of Medicine. He has received the Healthy American Fitness Leader Award from the President’s Council on Physical Fitness and Sports, the Lifetime Achievement Award from the International Association of Fitness Professionals, the Hall of Fame Award from the International Fitness Professionals Association, the Alumni Recognition Award from the Pennsylvania State University, and the Marla Richmond Memorial Education Award from the Medical Fitness Association.
Wayne Westcott, PhD
Quincy College, USA
Strength Training Protocols
Health-Related effects of Resistance Exercise
Joachim Uys, PhD
Medical University of South Carolina, USA
William S. Jacobs, MD
Georgia Regents University, USA
Iatrogenic Pain/Substance Abuse
Impaired Health Professionals
Daniel H. Angres, MD
Northwestern Feinberg School of Medicine, USA
David Han, PhD
University of Texas at San Antonio, USA
Medical Data Analytics
Competing Risk Analysis
Adi Jaffe, PhD
Alternatives Behavioral Health, USA
Counseling and Clinical Strategies
Substance Use Disorders (SUD)
Aviv Weinstein, PhD
Hadassah Medical Organization, Israel
Pharmacological and Psychological Treatment of Drug
Alcohol and Behavioral Addictions
Dr. Bowirrat has completed his PhD in 2002 from Tel Aviv University and Post-Doc in 2003 from Boston University school of Medicine. He published large number of articles on many topics in neurology, epidemiology, genetics and behavioral neuroscience and participated in a large number of conferences worldwide (USA, CANADA, EUROPE and other countries).
Dr. Bowirrat held many administrative positions and also served as Dean in Mar-Elias campus, branch of the University of Indianapolis, Manager of the scientific and technological topics at the ministry of science and technology, helped organize conferences, and contributed greatly to the higher education of Arab students in various institutes. Dr. Bowirrat involvements are in various administrative and educational activities in Colleges and Universities testify for his keen interest in community activities. He has both MD and PhD degrees, and had worked in a large number of institutions, specializing in clinical neurology, genetics, and epidemiology. He had extensive teaching and administrative experience, and served as a consultant and scientific Manager in the Ministry of Science in Israel.
A. Bowirrat, PhD
The Nazareth English Hospital (EMME), Israel
John J. Giordano, DMD
National Institute of Holistic Addiction Studies, USA
Reward Deficiency Syndrome
Deborah Matteliano, PhD
State University of New York, Buffalo, USA
Prescription Drug Abuse
Ioannis N. Mavridis, MD, PhD
K.A.T.-N.R.C. General Hospital of Attica, Greece
Deep Brain Stimulation
Dr. Anish Bajaj has practiced Chiropractic in New York City since 2001 with a focus on wellness and integrative healthcare strategies. Following graduation from State University of New York at Geneseo, Dr. Bajaj pursued his Doctor of Chiropractic from Life University in Atlanta Georgia. He has been the Director of Neuromuscular, Skeletal and Vascular Diagnostics at world renowned brain anti-aging center, Path Medical, for the past 13 years and has served as their Executive Health Program Director since 2006. As a clinician Dr. Bajaj specializes in Sacro-Occiptal-Technique, Soft Tissue Orthopedics, Sports Chiropractic, Electro-Therapeutics and Spinal Stabilizing Foot Orthotics. He served on the Executive Board of the New York Chiropractic Council from 2008 to 2010 as the President of the Manhattan District. He co-founded the American Decompression Pro Chiropractors which introduced the patented Neuro-Oxy Spinal Decompression Technique. His research in the fields of electrotherapeutics and cognitive function correlations to bone metabolism has been published in peer-reviewed journals including BMC Endocrine Disorders. He has also authored articles on integrative care, extremity adjusting/sports chiropractic, and the advancement of chiropractic neurology. As an Anti-Aging expert Dr. Bajaj has served as Instructor for the American Academy of Anti-Aging Medicine and has lectured around the U.S. as well as in Paris, Singapore and Beijing as a guest of the World Congress on Anti-Aging. Dr Bajaj is currently working on advancement of EEG data utilization in research, clinician support and patient education applications.
Anish Bajaj, DC
Path Medical Clinics, USA
Heart Rate Variablity
Lisa J. Merlo, PhD, MPE
University of Florida, USA
Impaired Healthcare Professionals
Psychosocial Risk Factors
Prescription Drug Abuse
Dr. Richard Gustin is trained in pharmacology at Vanderbilt University and University of Washington, Dr. Gustin has been involved in translational neuroscience research, utilizing animal models of human disease. By integrating molecular, cellular, and behavioral approaches, his research aimed to develop a better understanding of the manifestation of disease states, as well as identifying the therapeutic potential of compounds in preventing or reversing disease. Focusing on how different forms of stress could alter molecular mechanisms of learning and memory, and neuronal circuitry driving animal behaviors, he has developed a foundation of understanding for the mechanisms underlying addiction. His current role as a medical science liaison with Orexo US, Inc., as a patient advocate, providing scientific and medical education and support to a variety of health care entities, as well as helping to foster research collaboration to advance our understanding of addiction, supporting comprehensive health care for patients to promote long-term recovery.
Richard Gustin, PhD
Learning & Memory
Opioid Receptor Systems
Eric R. Braverman, MD
University of Florida, USA
Brain Performance and Nutrition Studies
Leptin Blood Levels
Dr Schoenthaler J. Schoenthaler received his MA in sociology from Syracuse University in 1975 and his PhD in sociology from the State University of New York at Buffalo in 1980 with specializations in criminology and deviant behavior. He joined the faculty at California State University, Stanislaus in Turlock, California in 1982, developed its criminal justice major in 1983, was promoted to Associate Professor in 1985, and Professor in 1990. He was the 2nd Professor at Stanislaus to be awarded the “Outstanding Researcher and Creative Professor Award in 2001 and the Linus Pauling Ortho molecular Award for Outstanding Research the same year. These were due to his research on nutrition and human behavior that proceeded over three phases. From 1980 to 1984, he was the principal investigator in 14 open trials in 917 educational or correctional institutions. Each showed that when nutrition of children better matched the recommendations of the National Academy of Sciences Food and Nutrition Board for fruits, vegetables, and whole grains by limiting sweets and fats, academic success rose significantly and juvenile delinquency fell over 40% in New York, Virginia, Alabama, and California. In 1985, he led research teams in New York, California, Virginia and Oklahoma that conducted 7-day dietary analyses of incarcerated offenders and found that, in each state, those at high risk of being malnourished were significantly more likely to commit serious incidents such as assault and battery than those who were at low risk of being malnourished with differences reaching over 30%. His research also showed that malnutrition in correctional institutions was widespread due to many offenders avoiding essential food groups at meals or only consuming food from other sources. From 1986 until today, Professor Schoenthaler has been leading research teams in conducting parallel randomized controlled trials in Oklahoma, California, and Arizona on the effects of vitamins and minerals versus placebo on crime, delinquency, violence, verbal and non-verbal IQ, academic performance, brain function, and biochemical changes in blood among schoolchildren (elementary, junior high, and high school), incarcerated delinquents, and incarcerated adult felons. In each well-controlled randomized trial, participants in the correctional system given active tablets produced significantly less crime and delinquency (28 to 41%) and often normalized blood chemistry and brain function. Among schoolchildren on active tablets, school suspensions fell 47% more than controls while both non-verbal intelligence and academic performance rose significantly. Three English and Dutch research teams have successfully replicated these findings among both schoolchildren and confined felons. Professor Schoenthaler has created over 150 peer reviewed publications, grants, and/or professional publications.
Stephen J. Schoenthaler, PhD
California State University, USA
Dr. Thomas McLaughlin was born in Staten Island, NY and studied at St. Peter’s Prep, a Jesuit high school, in Jersey City. He received his BA at St. Peter’s College, with a major in Psychology and a minor in Philosophy.
Dr. McLaughlin spent the following year as a Fulbright Scholar at the Johannes Gutenberg University, in Mainz, Germany. Following this, he received an NIMH Fellowship to study Clinical Psychology at Boston University, where he received his M.A. and Ph.D. degrees. Dr. McLaughlin doctoral dissertation involved the use of Feedback Electroencephalography to study Attention in Schizophrenic patients.
Following these studies, he worked as a Clinical Psychologist for four years and, then, entered the New Jersey College of Medicine, from which he obtained my M.D. in 1980. Dr. McLaughlin internship was done at the Hackensack University Medical Center. Following this, he did a Neurology Residency at Boston University. After my neurological training, he entered the Psychiatry Residency Program at McLean Hospital, a Harvard Teaching Hospital, in Belmont MA, where he served as a Teaching Fellow as well.
Since becoming separately Board-Certified in both Neurology and Psychiatry, he have practiced out-patient Psychiatry, while also carrying out rCBF/SPECT brain-imaging research at the laboratory of Professor Niels Lassen in Copenhagen..
Dr. Mclaughlin first became aware of “Reward Deficiency Syndrome” seven years ago and his clinical work has been informed by its findings and theory. Dr. McLaughlin currently applies it to the diagnosis and treatment of Tourette’s syndrome, ADHD, and Substance-Dependent patients.
Thomas McLaughlin, MD
Center For Psychiatric Medicine, Massachusetts, USA
Habibeh Khoshbouei, PhD
University of Florida, USA
Neurological and Neuropsychiatric Disorders
Cynthia Stuhlmiller, PhD, MS, BSN, RN, FAAN, is Professor of Rural Nursing at the University of New England School of Health, Armidale, Australia. She has been a clinical chair in mental health nursing since 1997 and has held academic appointments in California, Norway, New Zealand, Sydney, Adelaide, Hawaii and United Kingdom. Cynthia’s clinical and research focus is in areas of traumatic stress, psychological therapies such as computer-aided CBT, action-based and PBL learning, clinical supervision, and health self-management. She is co-author of the New England Framework of Guided Self-health-- developed to address physical and psychological conditions including addiction. Cynthia is involved in a wide variety of local, national and international collaborative projects and leads a large grant supporting a student-led clinic in a rural indigenous community in New South Wales Australia.
Cynthia Stuhlmiller, RN, MS, DNSc
University of New England, Australia
Action-Based and PBL Learning
Barry Tolchard, PhD
University of New England, Australia
Suicide and Mental Health
Psychosocial Aspects of Gambling
Dr. Csaba Barta is currently an Assistant Professor at the Institute of Medical Chemistry, Molecular Biology and Pathobiochemisry at Semmelweis University, Budapest, Hungary. He joined the Laboratory of Molecular Genetics as a graduate medical student and later defended his Ph.D. theses on the analysis, genotyping and prenatal diagnosis of monogenic disorders. Earlier he implemented genetic screening of steroid 21-hydroxylase deficiency in Hungary and also applied it for the first prenatal diagnosis case of congenital adrenal hyperplasia in the country. He was also working on the detection of point mutations in the plasma cholinesterase (BCHE) gene in children with complications during anesthesia and in their families. Apart from these studies he was involved in our investigations concerning methodological advances in genotyping, as well.
As a molecular geneticist his main research interest shifted to the field of psychiatric genetics. Since 2001 he has been responsible for genetic association studies of the dopamine and the serotonin systems in several clinical populations, such as substance dependence (mainly heroine, alcohol and nicotine), Tourette’s syndrome, ADHD, etc. He is involved in a number of large international collaborations, eg. the European Network for the Study of Gilles de la Tourette Syndrome (COST Action BM0905) and TS-Eurotrain: Interdisciplinary training network for Tourette Syndrome (FP7-PEOPLE-2012-Marie Curie ITN), as well as the International Consortium on ADHD and Substance Abuse (ICASA).
He also takes part in the biochemistry tutoring of medical students in the Hungarian, English and German programs of Semmelweis University.
Csaba Barta, MD, PhD
Semmelweis University, Hungary
James Fratantonio, Pharm. D
Dominion Diagnostics, USA
Lisa Marzilli, Pharm. D
Dominion Diagnostics, USA
Frederick G. Moeller, MD
Virginia Commonwealth University, USA
Traumatic Brain Injury
Barry Setlow, PhD
University of Florida College of Medicine, USA
Dr. Adriaan Bruijnzeel is an Associate Professor in the Department of Psychiatry at the University of Florida. He received his PhD in Neuroscience from Utrecht University (The Netherlands) and then did a postdoc in the Department of Neuropharmacology at the Scripps Research Institute in San Diego (USA). The Bruijnzeel-lab is located in the McKnight Brain Institute at the University of Florida and studies the neurobiology underlying nicotine, alcohol, and cannabis dependence. Our research suggests that a dysregulation of brain stress systems contributes to the brain reward deficit associated with drug withdrawal and stress-induced reinstatement of drug seeking. The studies point to a critical role of stress peptides such as corticotropin-releasing factor, alpha-melanocyte stimulating hormone (α-MSH), and vasopressin in nicotine withdrawal and relapse. In addition to this, our laboratory has investigated the effects of tobacco smoke, opioids, and alcohol on brain reward function and characterized the behavioral effects of tobacco and cannabis smoke. Dr. Bruijnzeel has received grant support from the National Institutes of Health (NIH), Flight Attendant Medical Research Institute (FAMRI), and the James and Esther King Biomedical Research Program. He has served as grant reviewer for the NIH, Italian Ministry of Health, National Science Center (Poland), Canadian Tobacco Control Research Initiative, Michael Smith Foundation for Health Research (Canada), Canadian Institutes of Health Research (Canada), and the Medical Research Council (United Kingdom).
Adriaan W. Bruijnzeel, PhD
University of Florida, USA
Bernard William (Bill) Downs
Victory Nutrition International Inc., USA
RDS Spectrum Disorders
Chronic Degenerative Diseases
Claudia Fahlke, PhD
University of Gothenburg, Sweden
Valerie Voon, MD, PhD
University of Cambridge, UK
Carolyn Coker Ross, MD, MPH
The Recovery Village at Palmer Lake - a subsidiary of Advanced Recovery Systems, USA
Alcohol and Drug Dependence